233 related articles for article (PubMed ID: 11831890)
1. Synthesis, biological activity, and molecular modeling investigation of new pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine derivatives as human A(3) adenosine receptor antagonists.
Baraldi PG; Cacciari B; Moro S; Spalluto G; Pastorin G; Da Ros T; Klotz KN; Varani K; Gessi S; Borea PA
J Med Chem; 2002 Feb; 45(4):770-80. PubMed ID: 11831890
[TBL] [Abstract][Full Text] [Related]
2. Pyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidine derivatives as highly potent and selective human A(3) adenosine receptor antagonists: influence of the chain at the N(8) pyrazole nitrogen.
Baraldi PG; Cacciari B; Romagnoli R; Spalluto G; Moro S; Klotz KN; Leung E; Varani K; Gessi S; Merighi S; Borea PA
J Med Chem; 2000 Dec; 43(25):4768-80. PubMed ID: 11123985
[TBL] [Abstract][Full Text] [Related]
3. Pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine derivatives as adenosine receptor antagonists. Influence of the N5 substituent on the affinity at the human A 3 and A 2B adenosine receptor subtypes: a molecular modeling investigation.
Pastorin G; Da Ros T; Spalluto G; Deflorian F; Moro S; Cacciari B; Baraldi PG; Gessi S; Varani K; Borea PA
J Med Chem; 2003 Sep; 46(20):4287-96. PubMed ID: 13678407
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis, and biological evaluation of C9- and C2-substituted pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines as new A2A and A3 adenosine receptors antagonists.
Baraldi PG; Fruttarolo F; Tabrizi MA; Preti D; Romagnoli R; El-Kashef H; Moorman A; Varani K; Gessi S; Merighi S; Borea PA
J Med Chem; 2003 Mar; 46(7):1229-41. PubMed ID: 12646033
[TBL] [Abstract][Full Text] [Related]
5. Fluorosulfonyl- and bis-(beta-chloroethyl)amino-phenylamino functionalized pyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidine derivatives: irreversible antagonists at the human A3 adenosine receptor and molecular modeling studies.
Baraldi PG; Cacciari B; Moro S; Romagnoli R; Ji Xd ; Jacobson KA; Gessi S; Borea PA; Spalluto G
J Med Chem; 2001 Aug; 44(17):2735-42. PubMed ID: 11495585
[TBL] [Abstract][Full Text] [Related]
6. The significance of 2-furyl ring substitution with a 2-(para-substituted) aryl group in a new series of pyrazolo-triazolo-pyrimidines as potent and highly selective hA(3) adenosine receptors antagonists: new insights into structure-affinity relationship and receptor-antagonist recognition.
Cheong SL; Dolzhenko A; Kachler S; Paoletta S; Federico S; Cacciari B; Dolzhenko A; Klotz KN; Moro S; Spalluto G; Pastorin G
J Med Chem; 2010 Apr; 53(8):3361-75. PubMed ID: 20307065
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis, and biological evaluation of new 8-heterocyclic xanthine derivatives as highly potent and selective human A2B adenosine receptor antagonists.
Baraldi PG; Tabrizi MA; Preti D; Bovero A; Romagnoli R; Fruttarolo F; Zaid NA; Moorman AR; Varani K; Gessi S; Merighi S; Borea PA
J Med Chem; 2004 Mar; 47(6):1434-47. PubMed ID: 14998332
[TBL] [Abstract][Full Text] [Related]
8. Synthesis, biological properties, and molecular modeling investigation of the first potent, selective, and water-soluble human A(3) adenosine receptor antagonist.
Maconi A; Pastorin G; Da Ros T; Spalluto G; Gao ZG; Jacobson KA; Baraldi PG; Cacciari B; Varani K; Moro S; Borea PA
J Med Chem; 2002 Aug; 45(17):3579-82. PubMed ID: 12166930
[TBL] [Abstract][Full Text] [Related]
9. New 2-arylpyrazolo[4,3-c]quinoline derivatives as potent and selective human A3 adenosine receptor antagonists.
Baraldi PG; Tabrizi MA; Preti D; Bovero A; Fruttarolo F; Romagnoli R; Zaid NA; Moorman AR; Varani K; Borea PA
J Med Chem; 2005 Jul; 48(15):5001-8. PubMed ID: 16033279
[TBL] [Abstract][Full Text] [Related]
10. Pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine derivatives as highly potent and selective human A(3) adenosine receptor antagonists.
Baraldi PG; Cacciari B; Romagnoli R; Spalluto G; Klotz KN; Leung E; Varani K; Gessi S; Merighi S; Borea PA
J Med Chem; 1999 Nov; 42(22):4473-8. PubMed ID: 10579811
[No Abstract] [Full Text] [Related]
11. 7-Substituted 5-amino-2-(2-furyl)pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines as A2A adenosine receptor antagonists: a study on the importance of modifications at the side chain on the activity and solubility.
Baraldi PG; Cacciari B; Romagnoli R; Spalluto G; Monopoli A; Ongini E; Varani K; Borea PA
J Med Chem; 2002 Jan; 45(1):115-26. PubMed ID: 11754583
[TBL] [Abstract][Full Text] [Related]
12. Exploring the directionality of 5-substitutions in a new series of 5-alkylaminopyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidine as a strategy to design novel human a(3) adenosine receptor antagonists.
Federico S; Ciancetta A; Sabbadin D; Paoletta S; Pastorin G; Cacciari B; Klotz KN; Moro S; Spalluto G
J Med Chem; 2012 Nov; 55(22):9654-68. PubMed ID: 23098605
[TBL] [Abstract][Full Text] [Related]
13. Pyrrolo- and pyrazolo-[3,4-e][1,2,4]triazolo[1,5-c]pyrimidines as adenosine receptor antagonists.
Baraldi PG; Saponaro G; Aghazadeh Tabrizi M; Baraldi S; Romagnoli R; Moorman AR; Varani K; Borea PA; Preti D
Bioorg Med Chem; 2012 Jan; 20(2):1046-59. PubMed ID: 22204739
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and biological studies of a new series of 5-heteroarylcarbamoylaminopyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidines as human A3 adenosine receptor antagonists. Influence of the heteroaryl substituent on binding affinity and molecular modeling investigations.
Pastorin G; Da Ros T; Bolcato C; Montopoli C; Moro S; Cacciari B; Baraldi PG; Varani K; Borea PA; Spalluto G
J Med Chem; 2006 Mar; 49(5):1720-9. PubMed ID: 16509587
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and structure-activity relationships of a new set of 1,2,4-triazolo[4,3-a]quinoxalin-1-one derivatives as adenosine receptor antagonists.
Colotta V; Catarzi D; Varano F; Filacchioni G; Martini C; Trincavelli L; Lucacchini A
Bioorg Med Chem; 2003 Aug; 11(16):3541-50. PubMed ID: 12878146
[TBL] [Abstract][Full Text] [Related]
16. Does the combination of optimal substitutions at the C²-, N⁵- and N⁸-positions of the pyrazolo-triazolo-pyrimidine scaffold guarantee selective modulation of the human A₃ adenosine receptors?
Cheong SL; Dolzhenko AV; Paoletta S; Lee EP; Kachler S; Federico S; Klotz KN; Dolzhenko AV; Spalluto G; Moro S; Pastorin G
Bioorg Med Chem; 2011 Oct; 19(20):6120-34. PubMed ID: 21908194
[TBL] [Abstract][Full Text] [Related]
17. 7-Deazaadenines bearing polar substituents: structure-activity relationships of new A(1) and A(3) adenosine receptor antagonists.
Hess S; Müller CE; Frobenius W; Reith U; Klotz KN; Eger K
J Med Chem; 2000 Nov; 43(24):4636-46. PubMed ID: 11101355
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis, and biological evaluation of a second generation of pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines as potent and selective A2A adenosine receptor antagonists.
Baraldi PG; Cacciari B; Spalluto G; Bergonzoni M; Dionisotti S; Ongini E; Varani K; Borea PA
J Med Chem; 1998 Jun; 41(12):2126-33. PubMed ID: 9622554
[TBL] [Abstract][Full Text] [Related]
19. Synthesis, CoMFA analysis, and receptor docking of 3,5-diacyl-2, 4-dialkylpyridine derivatives as selective A3 adenosine receptor antagonists.
Li AH; Moro S; Forsyth N; Melman N; Ji XD; Jacobson KA
J Med Chem; 1999 Feb; 42(4):706-21. PubMed ID: 10052977
[TBL] [Abstract][Full Text] [Related]
20. The Influence of the 1-(3-Trifluoromethyl-Benzyl)-1H-Pyrazole-4-yl Moiety on the Adenosine Receptors Affinity Profile of Pyrazolo[4,3-e][1,2,4]Triazolo[1,5-c]Pyrimidine Derivatives.
Federico S; Redenti S; Sturlese M; Ciancetta A; Kachler S; Klotz KN; Cacciari B; Moro S; Spalluto G
PLoS One; 2015; 10(12):e0143504. PubMed ID: 26625265
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
